Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

Leave a Reply

Your email address will not be published.

You May Also Like

LNCT Member Newsletter February 2021

LNCT UPDATES NEW LNCT BRIEF: Mobilizing Resources for Immunization in Decentralized Health Systems National immunization programs and immunization partners may need to consider new strategies to mobilize sufficient funding for immunization at subnational levels. This new LNCT brief outlines some of the key challenges found across LNCT countries with decentralized systems and offers several promising strategies for NIPs to … Continued

COVAX Application Materials for AMC Eligible Economies Now Available

The COVAX Facility released the application and guidance documents (“application package”) for eligible economies to (i) confirm participation in the COVAX Facility and (ii) request support as part of COVAX. This comprises COVID-19 vaccines, as well as Cold Chain Equipment and Technical Assistance needed to prepare for the delivery of COVID-19 vaccines.  All 92 AMC Eligible … Continued

LNCT Member Newsletter July 2020

LNCT Updates Materials from Two Recent LNCT Webinars Now Available Online On June 23, LNCT held a webinar, Assessing Bottlenecks to Adequate and Predictable Vaccine Financing. The World Bank presented their tool which aims to help country counterparts pinpoint the root causes of bottlenecks that affect adequate and reliable vaccine financing. The materials from the webinar, including … Continued